Physicians will not routinely prescribe promising therapies, and insurance may not cover them unless rigorous clinical trials prove their efficacy and define their toxicity. We believe that rigorous trials are the only way to formally validate promising therapies, the ideas for which will emerge from analysis of I-SHARE data, and/or from promising preclinical studies and/or limited human observations.

GlobalCures will conceive, design, write and sponsor these clinical trials since the therapies in question are not financially rewarding enough for pharmaceutical or biotech companies to sponsor. Of course, this is the core mission of GlobalCures, the primary reason for its existence! We must therefore rely on you - the patient - to fund these trials, though we will also seek funding from foundations and government agencies. Success will be measured by the number of new validated therapies that emerge. Even therapies that fail could be regarded as “successes” in that this data will ensure that patients do not undergo these therapies and waste their valuable money and time. The latter issue is of particular importance for cancer patients or those with other rapidly progressing diseases who have little time to
waste.

Finally, a word about how these programs are interconnected. The I-FIND and I-SHARE programs were conceived later but form logical preceding steps to I-FUND. The moneys needed to execute I-FUND are significantly higher than those needed to get I-FIND and I-SHARE off the ground and the background work done for I-FIND and I-SHARE (especially in identifying, conceptualizing and prioritizing promising therapies) will be useful for I-FUND.

Philosophy on information

As stated above, we will strive to make our information unbiased, scientifically rigorous, up-to-date and comprehensive. The underlying
principle is simple: we will provide information that we would appreciate receiving if we were in your shoes.

Unbiased - We pride ourselves on providing you the most objective data. Even the best intentioned physicians have inherent biases: they have certain treatment philosophies and will be most familiar with trials and options that are practiced by their colleagues in the setting in which they reside and will likely provide you the most information on trials they may be playing a role in.

Scientific rigor - We will evaluate existing data as well as treatment options with the highest level of scientific and clinical rigor.

Up-to-date - Our information will be updated on a regular basis every few weeks so that it is current.

Comprehensive - In today's world of information overload, even the best physicians cannot purport to know the many treatment options that exist. Our group of physician-scientists and physicians from all over the world and the experiences of our patients will ensure that their collective wisdom is reflected in the information that we provide.